Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.52 |
| ▸ | GRPR | P30550 | 4/20 | 0.49 |
| ▸ | CCKBR | P32239 | 4/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29816574 | 0.96 | KEAP1 (0.49) | KEAP1GRPRCCKBRREN | |
| SCHEMBL31332128 | 0.89 | KDM1A (0.57) | KEAP1REN | |
| SCHEMBL30231927 | 0.85 | REN (0.57) | REN | |
| SCHEMBL11309694 | 0.85 | OPRM1 (0.52) | CCKBR | |
| SCHEMBL11309707 | 0.85 | OPRM1 (0.52) | CCKBR | |
| SCHEMBL29351536 | 0.83 | OPRM1 (0.54) | CCKBR | |
| SCHEMBL30325318 | 0.82 | CTSC (0.47) | KEAP1REN | |
| SCHEMBL22686941 | 0.81 | REN (0.56) | REN | |
| SCHEMBL30892690 | 0.81 | CALCRL (0.50) | KEAP1CCKBRREN | |
| SCHEMBL31154661 | 0.81 | MAPK8 (0.48) | KEAP1CCKBRREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220288028-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2022-09-15 | — | — | US | disclosed |
| CN-114206849-A | Therapeutic methods for treating non-infectious ocular immunoinflammatory disorders | 斯格本斯眼科研究所有限公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288028-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | MSR1, LTB4R2, LTB4R | KEAP1 2295/4885GRPR 249/4885CCKBR 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.